ANALYSIS: The High Court’s recent decision to reverse the liquidator’s fees unearthed some curious conduct.
ANALYSIS: NBR Listers’ pharma company cleared a major FDA hurdle last week but winning the US is far from assured.
ANALYSIS: A search fund helps a keen entrepreneur parachute into the CEO seat of an existing business.
ANALYSIS: The brakes are on for the housing construction sector, but it’s way too soon to shout about shortages.
ANALYSIS: There seems to be little political appetite to correct society’s inadequate provision of care for people’s final days, months, and years.
ANALYSIS: Building franchises trade on trust and reliability, but when the franchisee fails the customer protections are mixed.
ANALYSIS: More Kiwi companies are looking to the ASX for listing, but is the grass really greener over the Ditch for newer, smaller firms looking for capital?
ANALYSIS: What might a comprehensive review of the Companies Act look like?
ANALYSIS: While cuts next year still look likely, days of 0.25% official cash rate set to become stuff of folklore.
ANALYSIS: New Zealand and Australia feel the freeze from dwindling Chinese demand.
